Baseline tumour size is an independent prognostic factor for overall survival in PD-L1 ≥ 50% non-small cell lung cancer patients treated with first-line pembrolizumab
Titel:
Baseline tumour size is an independent prognostic factor for overall survival in PD-L1 ≥ 50% non-small cell lung cancer patients treated with first-line pembrolizumab
Auteur:
Bureau, Mathilde Chatellier, Thierry Perennec, Tanguy Goronflot, Thomas Greilsamer, Charlotte Chene, Anne-Laure Affi, Raafet Frampas, Eric Bennouna, Jaafar Pons-Tostivint, Elvire